Nuovo studio italiano conferma efficacia Inclisiran con una riduzione del colesterolo LDL del 60%

adnkronos

(Adnkronos) - Farmaco a mRNA dimezza i livelli di colesterolo con iniezioni semestrali. Sono i risultati dello studio CHOLINET, coordinato dal professore Perrone Filardi sull’impiego di Inclisiran: una riduzione del colesterolo LDL del 60%.

Transcript

00:00The management of hypercholesterolemia is fundamental for the prevention of cardiovascular diseases,

00:09one of the main causes of mortality on a global level.

00:12However, a persistent problem in the therapy against cholesterol is the adherence of patients to prescribed therapeutic regimes.

00:19Recently, the emergence of the Inclisiran drug, supported by the results of the Colinet study conducted by Professor Perrone Filardi,

00:27Director of the Department of Advanced Biomedical Sciences of the Federico II University of Naples,

00:32opened new perspectives to improve adherence to therapy in subjects who have already had an acute cardiovascular event,

00:38or with atherosclerotic disease in various districts, diabetics at cardiovascular risk and subjects with family hypercholesterolemia.

00:46The new drugs for the control of dyslipidemia, that is cholesterol and LDL,

00:51and in particular the drug-object of our study, which is called Inclisiran,

00:57are particularly important because they have a new mechanism of action, they are very effective,

01:02they are devoid of side effects and give an important adherence duration.

01:08Using RNA-interfering technology, Inclisiran silences a specific gene in the liver,

01:15thus reducing the production of LDL cholesterol, with an evident effectiveness and tolerance of the drug.

01:22LDL cholesterol is reduced by 51% in 3 months and even more than 60% in 9 months.

01:36This is especially true when, together with Inclisiran, there is also a substantive statin.

01:45Another important fact is that out of 650 patients, only 23, for various reasons, have abandoned the drug,

01:55never for important side effects, unfortunately, or in most cases,

02:02because their doctor believed that the added value of cholesterol was too low.

02:07We insist on saying that there is no value of cholesterol too low.

02:11Unlike traditional treatments that require daily assumptions,

02:15one of the main advantages of Inclisiran is its supply regime,

02:19which not only simplifies the therapeutic process, but also improves the adherence of patients.

02:25The adherence, which means that the patient maintains the therapy as prescribed by the doctor,

02:33was 93-94%.

02:36On the other hand, we explain it to ourselves, because these are drugs without side effects.

02:43The supply, so distanced over time, is very convenient for the patient,

02:49it does not involve particular precautions, even in terms of drug maintenance,

02:58of drug treatment at home.

03:05So it's a very simple thing that can be done, and this explains this high adherence.

03:11The new adherence to cholesterol therapy is a crucial challenge in the fight against cardiovascular diseases

03:17in a reimbursability regime for patients selected through simple processes and key steps.

03:24By addressing their specialist, but also their general medicine doctor,

03:28certainly the colleagues of the general medicine are well informed about this therapy

03:34and will be able to direct patients to the reference centers,

03:37where they are authorized to prescribe and formulate the therapeutic plan for reimbursability.

03:44With the advancement of research in the field of pharmacological therapy,

03:49and in particular of pharmacological and cardiovascular therapies,

03:53today we have injectable drugs that are extremely comfortable for the patient,

03:58extremely beneficial and extremely effective.

Category

Transcript

Recommended